Cargando…

Abediterol, a novel long-acting β(2)-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD

BACKGROUND: Abediterol is a novel, once-daily long-acting β(2)-agonist in development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with an anti-inflammatory agent. This Phase IIa, randomised, double-blind, crossover study investigated the bronchodilatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beier, Jutta, Pujol, Helena, Seoane, Beatriz, Jimenez, Eulalia, Astbury, Carol, Massana, Eric, Ruiz, Sandrine, de Miquel, Gonzalo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955259/ https://www.ncbi.nlm.nih.gov/pubmed/27439370 http://dx.doi.org/10.1186/s12890-016-0266-5

Ejemplares similares

A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β(2)-adrenergic agonist, in asthma; a Phase II, randomized study
por: Singh, Dave, et al.
Publicado: (2014)

Efficacy, safety, and tolerability of once‐daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7‐day, crossover study
por: Beier, Jutta, et al.
Publicado: (2017)

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
por: Jimenez, Eulalia, et al.
Publicado: (2020)

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
por: Singh, Dave, et al.
Publicado: (2020)

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies
por: Balaguer, Victor, et al.
Publicado: (2020)

Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives
por: Rhee, Chin Kook, et al.
Publicado: (2019)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD
por: Singh, Dave, et al.
Publicado: (2022)

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol
por: Beier, Jutta, et al.
Publicado: (2011)

Bronchodilators in COPD: Impact of β-agonists and anticholinergics on severe exacerbations and mortality
por: Salpeter, Shelley R
Publicado: (2007)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Optimization of Long-Acting Bronchodilator Dose Ratios Using Isolated Guinea Pig Tracheal Rings for Synergistic Combination Therapy in Asthma and COPD
por: Menchi, Elena, et al.
Publicado: (2022)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands
por: van Boven, Job FM, et al.
Publicado: (2016)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
por: Kang, Jieun, et al.
Publicado: (2017)

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
por: Beier, Jutta, et al.
Publicado: (2017)

Impact of bronchodilator therapy on exercise tolerance in COPD
por: Aguilaniu, B
Publicado: (2010)

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

Flow and volume response to bronchodilator in patients with COPD
por: Matteo, Vigna, et al.
Publicado: (2018)

Bronchodilator delivery with metered-dose inhaler during mechanical ventilation
por: Georgopoulos, Dimitris, et al.
Publicado: (2000)

Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators
por: Nicolini, Antonello
Publicado: (2012)

Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2013)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
por: Matera, Maria Gabriella, et al.
Publicado: (2015)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019)

Effect of theophylline on exercise capacity in COPD patients treated with combination long-acting bronchodilator therapy: a pilot study
por: Voduc, Nha, et al.
Publicado: (2012)

Dose-dependent Spasmolytic, Bronchodilator, and Hypotensive Activities of Panicum miliaceum L.
por: Saqib, Fatima, et al.
Publicado: (2022)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Stepwise management of COPD: What is next after bronchodilation?
por: Miravitlles, Marc, et al.
Publicado: (2023)

Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
por: Chin, Pik-Qi, et al.
Publicado: (2022)

Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial
por: Haney, Sarah, et al.
Publicado: (2005)

Short-acting β2-agonists (SABA) bronchodilator sales and outdoor mould in central France
por: Caillaud, D. M., et al.
Publicado: (2019)

Two vs four puffs of albuterol: does dose change bronchodilator response?
por: McLaughlin, Anne V, et al.
Publicado: (2019)

Anxiolytics for Bronchodilation: Refinements to GABA(A) Agonists for Asthma Relief
por: Nayak, Ajay P., et al.
Publicado: (2022)

A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD
por: Jara, Michele, et al.
Publicado: (2012)

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
por: Bishwakarma, Raju, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_js0ls63srnhplui2ovs53flg59